戻る Agenda
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Session Chair(s)
William Gregory, PHD
Senior Director, Safety and Risk Management, Pfizer Inc, United States
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Speaker(s)
Peter F. Bross, MD
Medical Review Officer OTAT, CBER, FDA, United States
Speaker
William Gregory, PHD
Senior Director, Safety and Risk Management, Pfizer Inc, United States
Speaker